跳至主要内容
临床试验/NL-OMON44118
NL-OMON44118已完成3 期

Efficacy and Safety of NNC 0129-0000-1003 during Surgical Procedures in Patients with Haemophilia A - Pathfinder3

ovo Nordisk0 个研究点目标入组 1 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Ongoing participation in the pathfinder2 (NN7088-3859) trial and having received *5 doses of N8-GP
  • - Undergoing major surgery

排除标准

  • - Known or suspected hypersensitivity to trial product including allergy to hamster protein or related products
  • - Previous withdrawal from the pathfinder2 (NN7088-3859) trial after administration of trial product, except interruption due to inclusion in this pathfinder3 trial (NN7088-3860)
  • - The receipt of any investigational medicinal product (except N8-GP) within 30 days prior to enrolment into the trial.
  • - FVIII inhibitors * 0.6 BU/mL at screening
  • - Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
  • - Immune modulating or chemotherapeutic medication

研究者

发起方
ovo Nordisk

相似试验